There are 3484 resources available
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
1277P - HRD status of patients with early stage non-small cell lung cancer
Presenter: Apostolos Klinakis
Session: Poster session 04
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
292P - Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Presenter: Paola Tiberio
Session: Poster session 02
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
1278P - ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
Presenter: Ernest Nadal
Session: Poster session 04